Assessing the Need for Cytomegalovirus Antiviral Stewardship in High-Risk Cardiothoracic Transplant Recipients

被引：0
|
作者：
Garcia, E. [1 ]
Huber, O. [1 ]
Fose, J. [1 ]
Saddler, C. [1 ]
Smith, J. [1 ]
Lowery, E. [1 ]
Dhingra, R. [1 ]
Jorgenson, M. [1 ]
机构：
[1] Univ Wisconsin Hosp & Clin, Madison, WI USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2023年 / 23卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
D124
引用
收藏
页码：S1115 / S1116
页数：2
相关论文
共 50 条
  • [21] Efficacy of Valganciclovir Plus Cytomegalovirus Immune Globulin for Prevention of Cytomegalovirus Disease in High-Risk Renal Transplant Recipients
    Maldonado, Angela Q.
    Bitterman, Amanda N.
    Ojogho, Okechukwu N.
    Bowen, Kurt A.
    Weeks, Douglas L.
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (04) : 548 - 549
  • [22] A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients
    Puttarajappa, Chethan M.
    Hariharan, Sundaram
    Smith, Kenneth J.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 13 (02): : 290 - 298
  • [23] Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients
    Toussaint, Nigel D.
    Tan, Marcus B. P.
    Nicholls, Kathy
    Walker, Rowan G.
    Cohney, Solomon J.
    NEPHROLOGY, 2011, 16 (01) : 113 - 117
  • [24] Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients
    Schaenman, Joanna
    Phonphok, Korntip
    Spanuchart, Ittikorn
    Duong, Tin
    Sievers, Theodore M.
    Lum, Erik
    Reed, Elaine F.
    Bunnapradist, Suphamai
    TRANSPLANT INFECTIOUS DISEASE, 2021, 23 (01)
  • [25] A Cytomegalovirus Antiviral Stewardship Program at a Large Transplant Center.
    Jorgenson, M.
    Descourouez, J.
    Felix, D.
    Saddler, C.
    Smith, J.
    Mandelbrot, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 1036 - 1036
  • [26] Prevention of cytomegalovirus infection and disease in high-risk renal transplant recipients with polyvalent intravenous immunoglobulins
    Séchet, A
    Bridoux, F
    Bauwens, M
    Abou Ayache, R
    Belmouaz, S
    Touchard, G
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (03) : 812 - 813
  • [27] The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
    Humar, A.
    Lebranchu, Y.
    Vincenti, F.
    Blumberg, E. A.
    Punch, J. D.
    Limaye, A. P.
    Abramowicz, D.
    Jardine, A. G.
    Voulgari, A. T.
    Ives, J.
    Hauser, I. A.
    Peeters, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) : 1228 - 1237
  • [28] Prophylactic oral Ganciclovir prevents cytomegalovirus disease in high-risk renal transplant recipients.
    Singer, GG
    Storch, GA
    Burton, KG
    Lippmann, BJ
    Buller, RS
    GaudreaultKeener, M
    Lowell, JA
    Shenoy, S
    Howard, TK
    Brennan, DC
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A3469 - A3469
  • [29] QUESTIONABLE BENEFIT OF PROPHYLACTIC ACYCLOVIR IN RENAL-TRANSPLANT RECIPIENTS AT HIGH-RISK FOR CYTOMEGALOVIRUS DISEASE
    CHITWOOD, KK
    HEIMDUTHOY, KL
    NEY, AL
    KASISKE, BL
    CLINICAL TRANSPLANTATION, 1993, 7 (04) : 320 - 324
  • [30] Role of quantitative human cytomegalovirus PCR in predicting antiviral treatment response among high-risk hematopoietic stem-cell transplant recipients
    A Safdar
    M Bruorton
    J P Henslee-Downey
    F van Rhee
    Bone Marrow Transplantation, 2004, 33 : 463 - 464
12345